Pregabalin Capsule
Product Images NDC 72658-0813

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72658-0813). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eskayef Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 8 (Figure0008)

A bar chart depicting responder rates (%) for three groups: placebo (22.6%), 2.5 mg/kg/day (29.1%), and 10 mg/kg/day (40.6%). The chart includes sample sizes (N) below each group: placebo (93), 2.5 mg/kg/day (103), and 10 mg/kg/day (96). The vertical axis represents responder rate percentage from 0 to 60%.*

FDA Label Image

Figure 1 (Figure001)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo across a range of pain improvement percentages from 0 to 100.*

FDA Label Image

Figure 2 (Figure002)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Two lines are shown: one for Pregabalin 100 mg three times a day and the other for placebo, illustrating comparative patient improvement in pain levels.*

FDA Label Image

Figure 3 (Figure003)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 75 mg, 150 mg, and 300 mg taken two times a day, and placebo. The graph shows greater percent improvement for higher doses of Pregabalin compared to placebo across a range of pain improvement percentages.*

FDA Label Image

Figure 4 (Figure004)

A line graph depicting percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing the treatment effects on pain improvement.*

FDA Label Image

Figure 5 (Figure005)

Line graph showing the percent of patients improved over a range of percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The vertical axis represents the percent of patients improved, while the horizontal axis represents percent improvement in pain from baseline, with separate lines for each treatment group.*

FDA Label Image

Figure 6 (Figure006)

A bar graph depicting responder rates (%) for different dosages of pregabalin compared to placebo in two separate studies labeled E1 and E3. Each study shows varying responder rates at multiple dosages, with higher rates observed at increased doses of pregabalin.*

FDA Label Image

Figure 7 (Figure007)

A line graph depicting seizure reduction as a percentage change from baseline plotted against dose in mg/day. The graph shows median seizure reduction for four studies identified by different symbols: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID, with significant p-values annotated on data points. The x-axis represents dose ranging from 0 to 600 mg/day, and the y-axis shows median seizure reduction up to 60%. Placebo dose is indicated at zero, with only statistically significant p-values noted on the graph.*

FDA Label Image

Figure 9 (Figure008)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and a placebo. The graph shows trends of pain improvement among these groups over a range of improvement levels.*

FDA Label Image

Figure 10 (Figure009)

A line chart comparing the estimated percentage of subjects without LTR (Loss to Response) over a 180-day period between Pregabalin and placebo groups. The y-axis shows the percentage from 0% to 100%, and the x-axis shows days from 0 to 180. The Pregabalin group shows a higher percentage of subjects without LTR over time compared to the placebo group, with distinct solid and dashed lines representing each group.*

FDA Label Image

Figure 11 (Figure010)

A line graph comparing percent of subjects improved on the vertical axis with percent improved from baseline to Week 12 BOCF on the horizontal axis for Pregabalin versus placebo. The graph shows two lines: a solid line representing Pregabalin and a dotted line representing placebo, indicating higher improvement rates with Pregabalin over placebo.*

FDA Label Image

Figure 12 (Figure011)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 16 in a BOCF analysis. It shows two curves representing Pregabalin and Placebo treatments, with the Pregabalin curve consistently above the Placebo curve, indicating a higher percentage of subjects improved.*

FDA Label Image

Formula (Formula001)

A formula illustration showing the calculation for creatinine clearance (CLCr) involving factors such as age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 specifically for female patients. This mathematical expression is typically used for renal function assessment.*

FDA Label Image

Pregablin-100-60s-v2 (Pregablin 100 60s V2)

Label for Pregabalin Capsules 100 mg by Eskayef Pharmaceuticals Limited, displaying storage instructions at controlled room temperature, packaging of 60 capsules, and a note to dispense the accompanying Medication Guide. The label includes NDC 72658-0811-1 and manufacturer information in Bangladesh.*

FDA Label Image

Pregablin-150-60s-v2 (Pregablin 150 60s V2)

Label for Pregabalin Capsules 150 mg, oral dosage form, manufactured by Eskayef Pharmaceuticals Limited. The label states storage instructions, dispensing guidance, and contains barcodes. The package contains 60 capsules and is marked for prescription use only.*

FDA Label Image

Pregablin-200-60s-v2 (Pregablin 200 60s V2)

Label for Pregabalin Capsules 200 mg oral dosage form by Eskayef Pharmaceuticals Limited. The label includes storage instructions, pharmacist dispensing notes, and states the package contains 60 capsules. Registration details such as NDC 72658-0849-1 and manufacturer address in Bangladesh are also displayed. The label features a barcode and a 2D barcode placeholder area.*

FDA Label Image

Pregablin-225-60s-v2 (Pregablin 225 60s V2)

Label for Pregabalin Capsules 225 mg by Eskayef Pharmaceuticals Limited. The label indicates storage instructions, prescription-only status, and a quantity of 60 capsules. Manufacturer address and a barcode are visible. The label includes a pharmacist note to dispense the medication guide with the product.*

FDA Label Image

Pregablin-25-60s-v2 (Pregablin 25 60s V2)

Label for Pregabalin Capsules 25 mg by Eskayef Pharmaceuticals Limited. The label includes storage instructions (20° to 25°C, excursions allowed), dosing directions referencing prescribing info, and states each capsule contains 25 mg pregabalin USP. Package contains 60 capsules and includes barcodes and manufacturing information for Eskayef Pharmaceuticals in Bangladesh.*

FDA Label Image

Pregablin-300-60s-v2 (Pregablin 300 60s V2)

Label for Pregabalin Capsules 300 mg by Eskayef Pharmaceuticals Limited shows dosage strength prominently on a white background with a pink highlight. The label states storage conditions, container type, quantity of 60 capsules, and includes manufacturer address in Bangladesh. Barcode and Rx only status are also visible.*

FDA Label Image

Pregabalin-50-60s-v2 (Pregablin 50 60s V2)

Label for Pregabalin Capsules 50 mg by Eskayef Pharmaceuticals Limited. The label indicates oral capsules in a 60 count package with storage instructions (20° to 25°C), dispensing instructions, and a barcode. Contains prescription-only information with manufacturer details in Bangladesh.*

FDA Label Image

Pregabalin-75-60s-v2 (Pregablin 75 60s V2)

Label for Pregabalin Capsules 75 mg, oral dosage form, containing 60 capsules. The label notes storage instructions, pharmacist dispensing directions, and manufacturer details as Eskayef Pharmaceuticals Limited in Bangladesh. The NDC is 72658-0810-1 and the product is identified as prescription only from SK+F.*

FDA Label Image

Structure (Structure0001v1)

Chemical structure of pregabalin showing its molecular formula with an isobutyl side chain, an amino group (NH2), and a carboxyl group (CO2H). The diagram highlights the stereochemistry of the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.